When was Immunai Technologies founded?

Immunai Technologies was founded in 2018 and became a unicorn in 2021, reaching the milestone in 3 years. It raised its 1st funding round 2 years after its incorporation.

Where is Immunai Technologies located?

Immunai Technologies is headquartered in United States.

Who is the current CEO of Immunai Technologies?

Noam Solomon of Immunai Technologies. They have also founded 1 company and are an angel investors in 1 startup.

How many employees does Immunai Technologies have?

As of Sep 30, 2026, the latest employee count at Immunai Technologies is 171.

Is Immunai Technologies a funded company?

Immunai Technologies is a funded company, having raised a total of $295M across 4 funding rounds to date. The company's 1st funding round was a $20M Seed round, raised on May 14, 2020.

How much is Immunai Technologies worth?

The latest valuation of Immunai Technologies is $1B as of Nov 20, 2025.

When was the latest funding round of Immunai Technologies?

Immunai Technologies' latest funding was a $215M Series B round on Oct 27, 2021, with participation from 6 investors.

Is Immunai Technologies a Genomics company?

The primary sectors of Immunai Technologies are Genomics and Life Sciences Tech.

Where does Immunai Technologies rank among its competitors?

Immunai Technologies ranks 15th amongst 670 active competitors, of which 249 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Strand Therapeutics, which secured $153M in May, 2025.

Who are the top competitors of Immunai Technologies?

Immunai Technologies' top competitors include Alnylam, Spark Therapeutics and Forge Biologics. Among them, Strand Therapeutics secured the most recent funding round in May, 2025.

Immunai Technologies - 2026 Company Profile, Team, Funding & Competitors

Sectors and market segments that Immunai Technologies operate in

Immunai Technologies serves in the Life Sciences, HealthTech market segments.The primary business model of Immunai Technologies are:

Company Details

Developer of next-generation of immunomodulatory therapeutics. It has a properitery therapeutic engine AMICA Annotated Multiomic Immune Cell Atlas that combines multi-omic single-cell analysis with machine learning and functional genomics to accelerates drug discovery and development for immune-modulating medicines.

Website: immunai.com
Social
Email ID: *****@immunai.com

Key Metrics

Founded Year

2018

Location

United States

Stage

Series B

Total Funding

$295M in 4 rounds

Latest Funding Round

Series B, Oct 27, 2021, $215M

Post Money Valuation

$1B as on Nov 20, 2025

Investors

Viola Group & 15 more

Ranked

15^th among 670 active competitors

Employee Count

171 as on Sep 30, 2026

Investment & Acquisitions

Nebion & 1 more

Similar Companies

Alnylam & 828 more

View Immunai Technologies' full profile

Immunai Technologies has raised a total funding of $295M over 4 rounds. Its first funding round was on May 14, 2020. Its latest funding round was a Series B round on Oct 27, 2021 for $215M. 6 investors participated in its latest round. Immunai Technologies has 16 institutional investors.

Here is the list of recent funding rounds of Immunai Technologies:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 27, 2021	$215M	Series B	$1B	-	Koch Disruptive Technologies	Talos, 8VC, Alexandria, Icon Ventures, Piedmont Capital
Feb 11, 2021	$60M	Series A	-	-	Schusterman, Dexcel, Catalio Capital Management	Viola Group, TLV Partners
Jan 01, 2021	$345K	Grant (prize money)	-	-	-	Europa

Access funding benchmarks and valuations. Sign up today!

View details of Immunai Technologies's funding rounds and investors

The founders of Immunai Technologies are Noam Solomon and Ansuman Satpathy. Noam Solomon is the CEO of Immunai Technologies.

Here are the details of Immunai Technologies' key team members:

Noam Solomon: Co-Founder & CEO of Immunai Technologies. They are also an angel investor in 1 startup.
Contact Info: 1 email address
Ansuman Satpathy: Co-Founder of Immunai Technologies and founder of 1 other company.
Contact Info: 1 email address and 1 phone number

View details of Immunai Technologies's Founder profiles and Board Members

Immunai Technologies' employee count trend

Immunai Technologies has 171 employees as of Sep 26. Here is Immunai Technologies's employee count trend over the years:

Employee count trend for Immunai Technologies

Uncover Immunai Technologies' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Immunai Technologies include Alnylam, Spark Therapeutics and Forge Biologics. Here is the list of Top 10 competitors of Immunai Technologies, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	80/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
3rd	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	RA Capital Management, Aisling Capital & 7 others	70/100
4th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
5th	DNAnexus 2009, Mountain View (United States), Series H	Provider of cloud-based genome informatics & data management platform	$473M	Google Ventures, TPG & 21 others	70/100
6th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	69/100
7th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
8th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Adage Capital Management ... & 10 others	69/100
9th	ElevateBio 2018, Cambridge (United States), Series D	Provider of transnational research for portfolio of cell and gene therapy	$1.25B	Matrix Capital Management, Invus & 16 others	68/100
10th	Krystal Biotech 2015, Pittsburgh (United States), Public	Developer of genetic medicines to treat rare diseases	$11.3M	Frazier Life Sciences, Danforth Advisors & 2 others	67/100
15th	Immunai Technologies 2018, United States, Series B	Developer of next-generation of immunomodulatory therapeutics	$295M	Icon Ventures, MIT Startup Exchange & 14 others	62/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Immunai Technologies's competitors? Click here to see the top ones

Immunai Technologies has acquired 2 companies including Nebion and Dropprint Genomics. Immunai Technologies has not made any investments as of now.

Here is the latest report on Immunai Technologies's sector:

Free

Life Sciences Tech - Sector Report

Edition: September, 2026 (83 Pages)

View all reports related to Immunai Technologies

Media has covered Immunai Technologies for a total of 5 events in the last 1 year, 2 of them have been about company updates and 1 about partnerships.